Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

10.82 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,719
Open 10.82
Bid (Size) 10.90 (10)
Ask (Size) 11.00 (10)
Prev. Close 10.82
Today's Range 10.82 - 10.82
52wk Range 10.75 - 23.10
Shares Outstanding N/A
Dividend Yield 10.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
From Organon & Co.
Via Business Wire
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
From Organon & Co.
Via Business Wire

Performance

YTD
-27.7%
-27.7%
1 Month
-30.7%
-30.7%
3 Month
-31.2%
-31.2%
6 Month
-39.7%
-39.7%
1 Year
-39.2%
-39.2%

More News

Read More
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Earnings Scheduled For February 13, 2025
Via Benzinga
Looking Into Organon's Recent Short Interest
Via Benzinga
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
From Organon & Co.
Via Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
High-Yield Healthcare: 3 Stocks With Strong Dividends
Via MarketBeat
Organon (OGN) Shares Skyrocket, What You Need To Know
Via StockStory
Topics Initial Public Offering
Exposures Securities Market
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Via StockStory
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
From Organon & Co.
Via Business Wire
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Via StockStory
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
From Organon & Co.
Via Business Wire
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
Via The Motley Fool
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 10.82
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 04/16/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.